0000899243-22-003306.txt : 20220126
0000899243-22-003306.hdr.sgml : 20220126
20220126183945
ACCESSION NUMBER: 0000899243-22-003306
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220124
FILED AS OF DATE: 20220126
DATE AS OF CHANGE: 20220126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Diamandis Peter
CENTRAL INDEX KEY: 0001528288
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41058
FILM NUMBER: 22559191
MAIL ADDRESS:
STREET 1: 4640 ADMIRALTY WAY
STREET 2: SUITE 500
CITY: MARINA DEL REY
STATE: CA
ZIP: 90292
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxxinity, Inc.
CENTRAL INDEX KEY: 0001851657
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 862083865
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1717 MAIN STREET
STREET 2: SUITE 3388
CITY: DALLAS
STATE: TX
ZIP: 75201
BUSINESS PHONE: (254) 244-5739
MAIL ADDRESS:
STREET 1: 1717 MAIN STREET
STREET 2: SUITE 3388
CITY: DALLAS
STATE: TX
ZIP: 75201
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-24
0
0001851657
Vaxxinity, Inc.
VAXX
0001528288
Diamandis Peter
C/O VAXXINITY, INC
1717 MAIN ST, STE 3388
DALLAS
TX
75201
1
0
0
0
Class A common stock
2022-01-24
4
M
0
652764
4.1192
A
729687
D
Class A common stock
271655
I
Held by spouse
Class B common stock
1099915
D
Stock Option (right to buy)
4.1192
2022-01-24
4
M
0
652764
0.00
D
2022-01-26
Class A common stock
652764
163191
D
These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest.
The Class B common stock is convertible into Class A common stock on a one-for-one basis and has no expiration date.
The Reporting Person held 815,955 of these stock options set to expire on 1/26/2022 at the time of the transaction. 80% of the stock options vested upon closing of the initial public offering, and the remaining 20% are expected to expire before meeting vesting conditions. Previously, these stock options were incorrectly reported as having an expiration date of the earlier of one year following vesting and 8/3/2031.
Rene Paula Molina, attorney-in-fact for Peter Diamandis
2022-01-26